Indian benchmark indices rebounded sharply on Friday, with the Sensex surging 769 points to 81,721 and the Nifty climbing 243 ...

At Teva, we are all in for better health. Increasing access to quality medicines is fundamental to improving the health of ...

Soros Fund Management took fresh stakes in Las Vegas Sands (LVS), with 807K shares, Redfin (RDFN), with 870.2K shares, and ...

A study reports that people living in lower income neighborhoods were at a higher risk for hidradenitis suppurativa.

The latest quarterly results from a couple of major technology companies have soothed concerns about AI demand that prevailed ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) ...

According to the TRC’s quarterly statistical report, cited by the Jordan News Agency, Petra, fixed-line voice service subscriptions reached some 486,000 by the end of Q4 2024, compared to 493,000 in ...

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Sustainability highlights In preparation for new reporting regulations, AstraZeneca combined its 2024 sustainability and annual reporting into one integrated publication. Details of performance ...

AstraZeneca PLC (NASDAQ:AZN – Free Report) – Zacks Research cut their Q4 2026 EPS estimates for AstraZeneca in a research report issued on Wednesday, April 9th. Zacks Research analyst R.

with sequential improvement in core platform business Assets under management grew by 26% to Rs 1.14 lakh crore as of March 2025 Vs Rs 91,370 crore as of March 2024 Assets under management in Q4 ...